Risk Assessment Strategy / Tools & Technology

Topic	Replies	Views	Activity
Carcinogenic Potency Database - Access free With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…	3	2510	August 22, 2022
About the Risk Assessment Strategy / Tools & Technology category	0	662	April 14, 2021
Less than daily administration	7	417	July 19, 2026
QSAR Toolbox - Free software. Any experience?	21	2500	June 27, 2026
Nitrosamine risk assessment in early clinical development	0	196	June 17, 2026
Removal of nitrosamine analysis from the specification	3	273	April 24, 2026
Excipient Selection Strategies to Mitigate Nitrosamine Risks Excipients	0	232	April 8, 2026
Excipient Nitrosamine Risk Assessment Tool	1	552	March 26, 2026
Limit Test for NDSRI Risk Assessment?	3	244	March 13, 2026
Chat GPT's answer about the risk assessment of nitrosamine in pharmaceuticals	33	4060	February 28, 2026
Nitrosamine Risk Assessment on DETA	0	163	February 22, 2026
Available Tools for Prediction of Potential Degradation Products from Nitrosation Reactions Drug_Substance_APIs , risk-assessment , NDSRI	4	323	February 4, 2026
Nitrosamine Purge Factor Calculation Drug_Substance_APIs	1	511	December 30, 2025
The Impact of API Synthesis Optimization on Reducing Nitrosamine Risk: A Technical Walkthrough risk-assessment	0	273	December 20, 2025
⚖️ Risk assessment not strong enough, specifically on related impurities containing secondary amine	24	2489	September 25, 2025
Stability in risk assessment report risk-assessment	12	694	September 10, 2025
Call to review USP Risk Assessment Review Toolbox	125	3916	August 20, 2025
Background on Purging Factor Calculation for your Risk Assessment featured , purge	7	1874	August 13, 2025
Nitrosamine Risk Mitigation Calculator (by DFE Pharma) NDSRI , featured	1	1544	August 11, 2025
Nitrosamines evaluation in transdermal patches	12	2200	July 16, 2025
CMO Nitrosamine Risk Assessment Drug_Substance_APIs , NDSRI , risk-assessment	7	550	June 27, 2025
How to decide if one anticancer drug is for advanced cancer? risk-assessment	12	822	June 13, 2025
📖 Drug Substance and Drug Product Workflows for Quality Risk Management for the Presence of Nitrosamines in Medicines-Pub risk-assessment , featured	2	1175	May 27, 2025
Can we bypass confirmatory testing of DP based on Theoretical Calc. of NDSRI's	9	1560	April 24, 2025
Nitrosamines in topical products	4	1311	April 15, 2025
NDSRI in finishe products risk-assessment	2	457	March 13, 2025
N-nitrosoamides - a horse of a different color Drug_Substance_APIs	54	7855	March 6, 2025
Risk Assessment and Management Strategy of Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for the Treatment of a Rare Disease- from Prediction to Control-Pub NDSRI	0	613	January 29, 2025
📽 Introduction to Using (Q)SAR for the Assessment of Potential Mutagenicity of Drug Impurities QSAR	0	299	October 30, 2024
🖥 Berkeley Madonna Software for Nitrosation Kinetic Calculations	5	927	October 10, 2024

Carcinogenic Potency Database - Access free

With discussions about limits and how they are establish, it’s an important reminder about the Carcinogenic Potency Database, now The Lhasa Carcinogenicity Database (LCDB). Below from Lhasa article: “5 things you should…